Bavarian Nordic A/S
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stenvall Tarja
- Full Time Employees
- 1,795
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Philip Heymans Alle 3 Hellerup CR Denmark 2900
- IPO Date
- Nov 2, 1998
- Website
- bavarian-nordic.com
- Similar Companies
- Business
- Bavarian Nordic A/S, a Danish biotechnology company founded in 1994 and headquartered in Hellerup, Denmark, develops, manufactures, and commercializes life-saving vaccines utilizing proprietary MVA-BN viral vector technology; its core marketed products include non-replicating smallpox and mpox vaccines (IMVAMUNE in Canada, IMVANEX in the EU, JYNNEOS in the US), rabies vaccines (Rabipur/RabAvert), tick-borne encephalitis vaccine (Encepur), oral cholera vaccine (Vaxchora), oral typhoid vaccine (Vivotif), and the chikungunya vaccine Vimkunya approved in the US and EU in 2025; it also supplies the Mvabea booster as part of Janssen's Ervebo regimen for Ebola and Marburg viruses. The company operates manufacturing facilities in Kvistgård, Denmark, and Thörishaus, Switzerland, with research and development sites in Martinsried, Germany, and offices across the United States, Canada, France, and other regions, serving governments for public health preparedness and private markets for travel vaccines in the US, Europe, and internationally. Recent strategic expansions include the 2019 acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline and the 2023 purchase of Vivotif, Vaxchora, and a chikungunya candidate from Emergent BioSolutions; in 2025, a proposed DKK 19 billion ($3 billion) all-cash takeover by a Nordic Capital and Permira consortium at DKK 233 per share was recommended by the board but terminated in November after receiving only 60% shareholder acceptance short of the 66.7% threshold, enabling the company to persist as an independent listed entity on Nasdaq Copenhagen focused on growth.
Company News
Bavarian Nordic (OTCMKTS:BVNRY) Shares Break Above 50 Day Moving Average – What’s Next?
Bavarian Nordic (OTCMKTS:BVNRY) Sees Significant Decrease in Short Interest
Bavarian Nordic A/S (BVNRY) Q2 2026 Earnings Call Transcript
Global warming widens spread of TBE, chikungunya, Bavarian Nordic boss says
Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript
Denmark's Bavarian Nordic raises 2026 forecast
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic A/S (BVNRY) Q4 2025 Earnings Call Transcript
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Bavarian Nordic CEO to Step Down After $3 Billion Bid Fails
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
Bavarian Nordic – Completion of Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Short Interest in Bavarian Nordic (OTCMKTS:BVNRY) Drops By 41.9%
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees
Bavarian Nordic A/S (BVNRY) Q3 2025 Earnings Call Transcript
Bavarian Nordic chair Debruyne steps down after failed takeover